跳至主要内容
临床试验/ACTRN12616001560482
ACTRN12616001560482终止2 期

The role of flumazenil infusion in the treatment of benzodiazepine withdrawal

Go Medical Industries Pty Ltd0 个研究点目标入组 28 人开始时间: 2016年11月11日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients with daily benzodiazepine use for at least 3 months at a diazepam equivalent dose of 10 mg per day or higher, who want to cease benzodiazepine use.

排除标准

  • Patients will be excluded if they suffer epilepsy or have a history of seizures or fitting, are pregnant or are breastfeeding, are co-dependent on alcohol, are under 18 years of age or are unable or unwilling to provide informed consent.

研究者

相似试验